Trif C, Harpaz D, Eltzov E, Parcharoen Y, Pechyen C, Marks R
Biosensors (Basel). 2024; 14(3).
PMID: 38534233
PMC: 10968443.
DOI: 10.3390/bios14030126.
Al-Khazaleh A, Zhou X, Bhuyan D, Munch G, Al-Dalabeeh E, Jaye K
Molecules. 2024; 29(2).
PMID: 38257323
PMC: 10821245.
DOI: 10.3390/molecules29020410.
Voicu V, Brehar F, Toader C, Covache-Busuioc R, Corlatescu A, Bordeianu A
Biomolecules. 2023; 13(9).
PMID: 37759788
PMC: 10526757.
DOI: 10.3390/biom13091388.
Gomez-Canas M, Rodriguez-Cueto C, Satta V, Hernandez-Fisac I, Navarro E, Fernandez-Ruiz J
Methods Mol Biol. 2022; 2576:67-94.
PMID: 36152178
DOI: 10.1007/978-1-0716-2728-0_6.
Woodman S, Antonopoulos S, Durham P
Front Pain Res (Lausanne). 2022; 3:809352.
PMID: 35295808
PMC: 8915558.
DOI: 10.3389/fpain.2022.809352.
Spinal astroglial cannabinoid receptors control pathological tremor.
Carlsen E, Falk S, Skupio U, Robin L, Pagano Zottola A, Marsicano G
Nat Neurosci. 2021; 24(5):658-666.
PMID: 33737752
PMC: 7610740.
DOI: 10.1038/s41593-021-00818-4.
Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options.
Lafreniere J, Kelly M
Neuronal Signal. 2020; 2(4):NS20170144.
PMID: 32714590
PMC: 7373237.
DOI: 10.1042/NS20170144.
The role of catecholamines in modulating responses to stress: Sex-specific patterns, implications, and therapeutic potential for post-traumatic stress disorder and opiate withdrawal.
Ross J, Van Bockstaele E
Eur J Neurosci. 2020; 52(1):2429-2465.
PMID: 32125035
PMC: 8351794.
DOI: 10.1111/ejn.14714.
Cannabinoid Delivery Systems for Pain and Inflammation Treatment.
Bruni N, Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F
Molecules. 2018; 23(10).
PMID: 30262735
PMC: 6222489.
DOI: 10.3390/molecules23102478.
Potential of Endocannabinoids to Control Bladder Pain.
Bjorling D, Wang Z
Front Syst Neurosci. 2018; 12:17.
PMID: 29867382
PMC: 5962905.
DOI: 10.3389/fnsys.2018.00017.
Endocannabinoids in Body Weight Control.
Horn H, Bohme B, Dietrich L, Koch M
Pharmaceuticals (Basel). 2018; 11(2).
PMID: 29849009
PMC: 6027162.
DOI: 10.3390/ph11020055.
Parameters of the Endocannabinoid System as Novel Biomarkers in Sepsis and Septic Shock.
Lafreniere J, Lehmann C
Metabolites. 2017; 7(4).
PMID: 29104224
PMC: 5746735.
DOI: 10.3390/metabo7040055.
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.
Scavone J, Sterling R, Van Bockstaele E
Neuroscience. 2013; 248:637-54.
PMID: 23624062
PMC: 3742578.
DOI: 10.1016/j.neuroscience.2013.04.034.
Cellular signal mechanisms of reward-related plasticity in the hippocampus.
Isokawa M
Neural Plast. 2012; 2012:945373.
PMID: 23213575
PMC: 3504448.
DOI: 10.1155/2012/945373.
The evolution and comparative neurobiology of endocannabinoid signalling.
Elphick M
Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3201-15.
PMID: 23108540
PMC: 3481536.
DOI: 10.1098/rstb.2011.0394.
Cannabinoid receptor signaling and modulation of monoamines: implications for psychiatric and neurological disorders.
Van Bockstaele E
Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(1):1-3.
PMID: 22251566
PMC: 4707950.
DOI: 10.1016/j.pnpbp.2012.01.002.
Endocannabinoids and traumatic brain injury.
Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R
Br J Pharmacol. 2011; 163(7):1402-10.
PMID: 21418185
PMC: 3165950.
DOI: 10.1111/j.1476-5381.2011.01343.x.
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.
Reggio P
Curr Med Chem. 2010; 17(14):1468-86.
PMID: 20166921
PMC: 4120766.
DOI: 10.2174/092986710790980005.
Migraine: an overview.
Salomone S, Caraci F, Capasso A
Open Neurol J. 2009; 3:64-71.
PMID: 19888434
PMC: 2771268.
DOI: 10.2174/1874205X00903010064.
Cannabis and psychosis/schizophrenia: human studies.
DSouza D, Sewell R, Ranganathan M
Eur Arch Psychiatry Clin Neurosci. 2009; 259(7):413-31.
PMID: 19609589
PMC: 2864503.
DOI: 10.1007/s00406-009-0024-2.
